BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32371123)

  • 21. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of health-related quality of life in Lithuanian brain tumor patients using the EORTC brain cancer module.
    Bunevičius A; Tamašauskas Š; Tamašauskas A; Deltuva V
    Medicina (Kaunas); 2012; 48(11):588-94. PubMed ID: 23455894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: Health-related quality of life final analysis from the Florence phase 3 trial.
    Meattini I; Saieva C; Miccinesi G; Desideri I; Francolini G; Scotti V; Marrazzo L; Pallotta S; Meacci F; Muntoni C; Bendinelli B; Sanchez LJ; Bernini M; Orzalesi L; Nori J; Bianchi S; Livi L
    Eur J Cancer; 2017 May; 76():17-26. PubMed ID: 28262584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial.
    Kepka L; Tyc-Szczepaniak D; Osowiecka K; Sprawka A; Trąbska-Kluch B; Czeremszynska B
    Clin Transl Oncol; 2018 Feb; 20(2):150-159. PubMed ID: 28616720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
    Noordman BJ; Verdam MGE; Lagarde SM; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB
    J Clin Oncol; 2018 Jan; 36(3):268-275. PubMed ID: 29161204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
    Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
    Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
    Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma.
    Scartoni D; Amelio D; Palumbo P; Giacomelli I; Amichetti M
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1615-1622. PubMed ID: 32200460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy.
    Versmessen H; Vinh-Hung V; Van Parijs H; Miedema G; Voordeckers M; Adriaenssens N; Storme G; De Ridder M
    BMC Cancer; 2012 Oct; 12():495. PubMed ID: 23098579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
    Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
    J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
    Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial.
    Zindler JD; Bruynzeel AME; Eekers DBP; Hurkmans CW; Swinnen A; Lambin P
    BMC Cancer; 2017 Jul; 17(1):500. PubMed ID: 28743240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
    King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
    Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.
    Habets EJ; Dirven L; Wiggenraad RG; Verbeek-de Kanter A; Lycklama À Nijeholt GJ; Zwinkels H; Klein M; Taphoorn MJ
    Neuro Oncol; 2016 Mar; 18(3):435-44. PubMed ID: 26385615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
    Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
    Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
    Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
    J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study.
    Witlox WJA; Ramaekers BLT; Joore MA; Dingemans AC; Praag J; Belderbos J; Tissing-Tan C; Herder G; Haitjema T; Ubbels JF; Lagerwaard J; El Sharouni SY; Stigt JA; Smit EF; van Tinteren H; van der Noort V; Groen HJM; De Ruysscher DKM
    Radiother Oncol; 2020 Mar; 144():65-71. PubMed ID: 31733490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.